Voriconazole and target-site penetration into human tissue by Weiler, Stefan et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open Access Meeting abstract
Voriconazole and target-site penetration into human tissue
Stefan Weiler1, Rosa Bellmann-Weiler2, Stefan Dunzendorfer3, 
Michael Joannidis3 and Romuald Bellmann*1,3
Address: 1Clinical Pharmacokinetics Unit, Laboratory of Inflammation Research, Department of Internal Medicine I, Innsbruck Medical 
University, 6020 Innsbruck, Austria, 2Infectious Diseases, Department of Internal Medicine I, Innsbruck Medical University, 6020 Innsbruck, 
Austria and 3Intensive Care Unit, Department of Internal Medicine I, Innsbruck Medical University, 6020 Innsbruck, Austria
Email: Romuald Bellmann* - romuald.bellmann@i-med.ac.at
* Corresponding author    
Background
Voriconazole (VOR) is an azole antifungal drug with
broad activity against Candida albicans, non-albicans Can-
dida and Aspergillus species. Oral and parenteral formula-
tions have similar pharmacokinetics and are used for the
treatment of life-threatening invasive fungal infections.
Materials and methods
Target-site penetration was evaluated in autopsy samples
(lung, brain, kidneys, liver, spleen, heart) of two patients
who had died during treatment with VOR. Patient 1 had
obtained a single-dose of VOR (200 mg), the interval
between the last administration and death was 36 hours.
Patient 2 was on VOR therapy under steady-state (day 10,
cumulative dose 3,800 mg). He died 12 hours after the
last VOR infusion. Tissue samples were obtained during
routine autopsy, homogenized, purified and quantified
by HPLC.
Results
The VOR concentrations in patient 2 exceeded those
measured in patient 1 in all tissue samples. The highest
levels were determined in the liver (4.21 ± 0.77 g/L) and
the kidneys (6.89 ± 0.06 g/L). Mean VOR lung concentra-
tion amounted to 1.30 ± 0.63 g/L (patient 1: 0.72 to 0.76
g/L; patient 2: 1.47 to 2.04 g/L). After a single administra-
tion VOR tissue levels in the brain were below the limit of
detection (<0.25 g/L) and achieved concentrations of 3.34
± 0.18 g/L under steady-state conditions. In the different
areas of the brain (cortex, hippocampus, nucleus cauda-
tus, medulla oblongata and cerebellum) similar VOR con-
centrations were found. VOR levels amounted to 1.31 ±
0.03 g/L and 2.95 ± 0.05 g/L in samples of the spleen of
patient 1 and 2, respectively. In the myocardium samples
of patient 1 VOR was not detectable, but reached a mean
concentration of 2.44 ± 0.25 g/L in patient 2.
Conclusion
Even after a single administration, VOR could be detected
in most tissues. Obviously, the drug accumulates in the
organs of its elimination, the liver and the kidneys. The
penetration into the brain and into the myocardium is
probably slower. The maximum lung concentrations
appear to be below the levels achieved in other tissues.
However, the levels may exceed the minimal inhibitory
concentrations of most relevant fungal pathogens.
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